


Product Name : BI-2865
Cat. No. : PC-20877
CAS No. : 2937327-93-8
Molecular Formula : C₂₃H₂₇N₇O₂S
Molecular Weight : 465.58
Target : Ras
Solubility : 10 mM in DMSO



Biological Activity

BI-2865 is a potent, inactive state selective, non-covalent **pan KRAS** inhibitor, binds to the GDP-loaded state of WT, G12C, G12D, G12V and G13D KRAS with high affinity (ITC K_d values, 10-40 nM), inactivates common cancer-causing KRAS mutants. BI-2865 inhibits the proliferation of isogenic G12C, G12D or G12V mutant KRAS expressing BaF3 cells with mean IC₅₀ of 140 nM.

BI-2865 shows comparable activity against KRAS G12C-expressing BaF3 cells to that of covalent KRAS G12C inhibitors BI-0474 and sotorasib.

BI-2865 inhibits the activation of KRAS splice variants 4A and 4B with an IC₅₀ of less than 10 nM, with little effect against NRAS and HRAS (IC₅₀=5-10 μM).

BI-2865 treatment inhibited ERK and RSK phosphorylation predominantly in KRAS mutant models (mean IC₅₀ roughly 150 nM for pERK and roughly 70 nM for pRSK), with only a small effect in WT or UAWT models.

BI-2865 suppresses MAPK output more potently in KRAS mutant models correlated, on average, with a more potent antiproliferative effect in a panel of 274 cancer cell lines.

References

Dongsung Kim, et al. *Nature*. 2023 May 31. doi: 10.1038/s41586-023-06123-3.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com